Takeda’s (NYSE: TAK ... almost a thousand for a disease like alpha-1 antitrypsin deficiency. After fractionation, you go through a process of purification and viral inactivation.

Takeda, a global biopharmaceutical company with a manufacturing site in Stanton Springs, unveiled its new Biomedical Waste ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...